ASTRAZENECA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,364 GBX | +2.22% |
|
+0.37% | +16.64% |
| 07:40pm | US Equity Indexes Little Changed as Fed Officials Pepper Views on Policy Path, Investors Brace for Nvdia's Earnings | MT |
| 07:09pm | US Equity Indexes Slightly Higher in Midday Trading | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
157.2
USD
Average target price
168.1
USD
Spread / Average Target
+6.94%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +16.64% | 238B | |
| +37.78% | 705B | |
| +32.82% | 583B | |
| -3.51% | 364B | |
| +19.94% | 332B | |
| +5.14% | 291B | |
| -4.13% | 210B | |
| +10.63% | 209B | |
| +9.32% | 169B | |
| -0.80% | 162B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- Advisers Urge Shareholders to Vote Against AstraZeneca CEO's Pay Plan